Neogenomics (NEO) Revenue (2010 - 2026)

Neogenomics (NEO) has 17 years of Revenue data on file, last reported at $201.7 million in Q2 2026.

• Quarterly Revenue rose 11.21% year-over-year to $201.7 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $766.3 million (up 11.19% YoY) and the FY2025 annual result came in at $727.3 million, up 10.11% from the prior year.
• Revenue rose to $201.7 million in Q2 2026, from $186.7 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $201.7 million in Q2 2026 to a low of $117.2 million in Q1 2022.
• A 5-year average of $159.9 million and a median of $160.4 million in 2024 frame the typical range for Revenue.
• Annual changes were most pronounced in 2022 — Revenue increased 1.42% — and 2023, when it increased 17.99%.
• Tracing NEO's Revenue over 5 years: stood at $138.7 million in 2022, then climbed by 12.15% to $155.6 million in 2023, then grew by 10.57% to $172.0 million in 2024, then gained by 10.56% to $190.2 million in 2025, then rose by 6.04% to $201.7 million in 2026.
• The last three Revenue figures came in at $201.7 million (Q2 2026), $186.7 million (Q1 2026), and $190.2 million (Q4 2025), per Business Quant data.